pentobarbital will decrease the extent or impact of linagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Use of other therapies is strongly encouraged when linagliptin is to be administered which has a CYP3A4 inducerbuprenorphine subdermal implant and pentobarbital the two increase sedation. Stay clear of or Use